Publications by authors named "Els Witteveen"

Claim this Profile
L
Long-term neurocognitive, psychosocial, and physical outcomes after prenatal exposure to radiotherapy: a multicentre cohort study of the International Network on Cancer, Infertility, and Pregnancy.
Indra A Van Assche, Kristel Van Calsteren, Jurgen Lemiere, Jana Hohmann, Jeroen Blommaert, Els P O Witteveen

Lancet Child Adolesc Health· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer.
Rhode Bijlsma, Roel Wouters, Hester Wessels, Stefan Sleijfer, Laurens Beerepoot, Els Witteveen

ESMO Open· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying patients with a history of ovarian cancer for referral for genetic counselling: non-randomised comparison of two case-finding strategies in primary care.
Charles W Helsper, Liesbeth M Van Vliet, Mary E Velthuizen, Niek J de Wit, Roy Ph Beijaert, Els O Witteveen

Br J Gen Pract· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, Sandro Pignata, Jonathan Ledermann, Els Witteveen

Int J Gynecol Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Michael Leonard Friedlander, Alan Covens, Rosalind M Glasspool, Felix Hilpert, Gunnar Kristensen, Els Witteveen

Int J Gynecol Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study.
Kristel Van Calsteren, René Verbesselt, Nelleke Ottevanger, Michael Halaska, Liesbeth Heyns, Els Witteveen

Acta Obstet Gynecol Scand· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients.
Jeanine M Roodhart, Marlies H Langenberg, Joost S Vermaat, Martijn P Lolkema, Arnold Baars, Els O Witteveen

Neoplasia· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.
Stephan A Veltkamp, Els O Witteveen, Angela Capriati, Attilio Crea, Fabio Animati

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
Jeanine M Roodhart, Marlies H Langenberg, Els Witteveen, Emile E Voest

Curr Clin Pharmacol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Jeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, Sandra A Radema, Rianne van Maanen, Els O Witteveen

Clin Cancer Res· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review.
Flora Vernooij, Peter Heintz, Els Witteveen, Yolanda van der Graaf

Gynecol Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Isa E L M Kuppens, Els O Witteveen, Roxanne C Jewell, Sandra A Radema, Elaine M Paul

Clin Cancer Res· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Tessa M Bosch, Alwin D R Huitema, Valerie D Doodeman, Robert Jansen, Els Witteveen

Clin Cancer Res· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
Laurens V Beerepoot, Sandra A Radema, Els O Witteveen, Tawnie Thomas, Catherine Wheeler

J Clin Oncol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.
Laurens V Beerepoot, Els O Witteveen, Gerard Groenewegen, William E Fogler, B Kim Leel Sim

Clin Cancer Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis